EDGAR·FLOW

GALECTIN THERAPEUTICS INC — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 78/100
What the filing says
On July 31, 2026, Galectin's Chairman Richard Uihlein converted $105.8M in debt ($91.0M principal + $14.8M accrued interest) into 34,376,167 shares of common stock, eliminating five of six credit facilities and strengthening the balance sheet. Concurrently, the company submitted a registrational Phase 3 protocol to FDA for belapectin in MASH cirrhosis with portal hypertension (primary endpoint: composite liver outcome); NAVIGATE Phase 2b/3 data presented at AASLD showed belapectin-treated patients had 15.9% placebo-adjusted improvement in ANTICIPATE-NASH CSPH risk (p=0.04). Q3 2026 cash position: $11.7M with $10M additional credit line available; company projects funding through June 2027.
Why this rating

Debt elimination ($105.8M ≈ 97% of market cap) dramatically improves solvency and runway; Phase 3 filing represents key inflection. Material positive for $109M company.

Tradability signal
NO TRADE

No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.04% over 4 hrs, n=508). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$3.04
+10 min · unknown
$3.06 ▲ 0.82%
+30 min · unknown
$3.08 ▲ 1.32%
+1 hr · unknown
$3.12 ▲ 2.80%
+4 hrs · unknown
$2.93 ▼ 3.46%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ GALT · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.